Atomic absorbers for controlling pulse propagation in resonators

We consider pulse propagation through a Fabry-Perot cavity with silver mirrors that contain macroscopic samples of resonant absorbers. We show that the pulse velocity can be tuned from subluminal to superluminal in a strongly coupled atom-cavity system. We delineate the effects of the interplay of cavity and absorbers. We demonstrate the saturation effects of pulse advancement with increasing mirror thickness and atomic damping

Control of superluminal transit through a heterogeneous medium

We consider pulse propagation through a two component composite medium (metal inclusions in a dielectric host) with or without cavity mirrors. We show that a very thin slab of such a medium, under conditions of localized plasmon resonance, can lead to significant superluminality with detectable levels of transmitted pulse. A cavity containing the heterogeneous medium is shown to lead to subluminal-to-superluminal transmission depending on the volume fraction of the metal inclusions. The predictions of phase time calculations are verified by explicit calculations of the transmitted pulse shapes. We also demonstrate the independence of the phase time on system width and the volume fraction under specific conditions.Comment: 21 Pages,5 Figures (Published in Journal of Modern Optics

Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries.

BACKGROUND: As global initiatives increase patient access to surgical treatments, there remains a need to understand the adverse effects of surgery and define appropriate levels of perioperative care. METHODS: We designed a prospective international 7-day cohort study of outcomes following elective adult inpatient surgery in 27 countries. The primary outcome was in-hospital complications. Secondary outcomes were death following a complication (failure to rescue) and death in hospital. Process measures were admission to critical care immediately after surgery or to treat a complication and duration of hospital stay. A single definition of critical care was used for all countries. RESULTS: A total of 474 hospitals in 19 high-, 7 middle- and 1 low-income country were included in the primary analysis. Data included 44 814 patients with a median hospital stay of 4 (range 2-7) days. A total of 7508 patients (16.8%) developed one or more postoperative complication and 207 died (0.5%). The overall mortality among patients who developed complications was 2.8%. Mortality following complications ranged from 2.4% for pulmonary embolism to 43.9% for cardiac arrest. A total of 4360 (9.7%) patients were admitted to a critical care unit as routine immediately after surgery, of whom 2198 (50.4%) developed a complication, with 105 (2.4%) deaths. A total of 1233 patients (16.4%) were admitted to a critical care unit to treat complications, with 119 (9.7%) deaths. Despite lower baseline risk, outcomes were similar in low- and middle-income compared with high-income countries. CONCLUSIONS: Poor patient outcomes are common after inpatient surgery. Global initiatives to increase access to surgical treatments should also address the need for safe perioperative care. STUDY REGISTRATION: ISRCTN5181700

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Study of asymmetric multilayered structures by means of nonreciprocity in phases

We study symmetric and asymmetric stratified media with resonant absorbers to bring out the role of inversion symmetry and absorption. We show that both can be probed using the reflected fields for excitation of the structure from opposite sides. The phase asymmetry is shown to bear the signature of broken inversion symmetry in lossless systems, while losses in addition lead to the nonreciprocity in the intensity reflection coefficient. We demonstrate how reflected pulses from opposite ends can reveal both of the aspects through their shapes and delays. Moreover, we demonstrate a great flexibility in manipulating the pulse velocities mediated by the resonant atom-field interaction

Self-similarity in nonclassical transmission through a fibonacci sequence of Gaussian barriers

We study quantum mechanical scattering by one-dimensional sequence of Gaussian barriers and calculate the transmission through such systems. We illustrate the physical aspects of resonance states and their coupling with the example of two and three barriers. Finally, we consider Fibonacci sequences of such barriers to demonstrate the properties of scaling, multifractality and self-similarity. These results are compared with those of periodic structures. All the calculations are based on the transfer matrix approach resulting from a fine segmentation of each barrier

Hybrid graphene/titania nanocomposite: Interface charge transfer, hole doping, and sensitization for visible light response

We demonstrated for the first time by large-scale ab initio calculations that a graphene/titania interface in the ground electronic state forms a charge-transfer complex due to the large difference of work functions between graphene and titania, leading to substantial hole doping in graphene. Interestingly, electrons in the upper valence band can be directly excited from graphene to the conduction band, that is, the 3d orbitals of titania, under visible light irradiation. This should yield well-separated electron−hole pairs, with potentially high photocatalytic or photovoltaic performance in hybrid graphene and titania nanocomposites. Experimental wavelength-dependent photocurrent generation of the graphene/titania photoanode demonstrated noticeable visible light response and evidently verified our ab initio prediction